The financials
Ocular Therapeutix, Inc. by the numbers
Ocular Therapeutix, Inc. (OCUL) reported revenue of $11M in Q1 2026 (quarter ended March 31, 2026), up 0.8% from the same quarter a year earlier. That came with a gross margin of 88% and net loss of $89M. For the full year FY2025, revenue was $52M (−18% year on year) and net income −$266M. Its largest product in 2024-Q3 was Collaboration at $78K, 50.0% of the disclosed total, just ahead of Otx Tic Product at 50.0%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $11M | $11M | +0.8% |
| Gross profit | $9.5M | $9.4M | +0.2% |
| Operating income | −$93M | −$64M | n/a |
| Net income | −$89M | −$64M | n/a |
| Diluted EPS | −$0.40 | −$0.38 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Collaboration | $78K | 50% |
| Otx Tic Product | $78K | 50% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $0.00
Segment Latestyear on year
- Collaboration--year on year --